Recommendation of the President – Fycompa (perampanel)
On 31 October 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 164/2025 on the appropriateness of granting approval for the reimbursement of the medicinal product Fycompa (perampanel) for the following indications: drug-resistant epilepsy, drug-resistant epilepsy with focal seizures